Table 2.

NET-directed therapeutic strategies

Biological target	Compound	Targeting disease	Study	Reference, Identifier
DNAse	Dornase Alfa	SARS-CoV-2	COVIDORNASE, Phase III	NCT04355364
			COVASE, Phase II	NCT04359654
			DORNASESARS2, Phase III	NCT04402970
		Respiratory failure after trauma	TRAUMADORNASE, Phase III	NCT03368092
		Ischaemic stroke	NETs-target, Phase II	NCT04785066
Histones	Heparin	Sepsis	Preclinical	133
	Non-coagulant heparin	Sepsis	Preclinical	134
	Chondroitin sulphate E	Endotoxaemia	Preclinical	135
	Anti-histone antibodies	Sepsis, kidney injury, atherosclerosis	Preclinical	111,136,137
	Anti-citrullinated antibodies	RA	Preclinical	138
PAD4	GSK199	Thrombosis, sepsis-induced coagulation	Preclinical	83,139
Microtubular function	Colchicine	Myocardial infarction	COLCOT	140
Gasdermin D	Disulfiram	SARS-CoV-2	DISCO, Phase II	NCT04485130
DEK	DEK aptamers	RA	Preclinical	25

NET, neutrophil extracellular trap; PAD4, protein-arginine deiminase type 4; RA, rheumatoid arthritis.